Aurobindo Pharma Limited has informed the Exchange about Completion of US FDA Inspection at Unit I of Eugia Pharma Specialities Ltd
AUROPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.0 pts more than Nifty Midcap 150 and 1.1 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The US FDA inspected Unit-I, a formulation manufacturing facility, of Eugia Pharma Specialities Ltd (Aurobindo Pharma's wholly owned subsidiary) located in Shameerpet, Telangana, from February 16 to February 27, 2026. The inspection concluded with 4 observations. The company has stated it will respond to the US FDA within the stipulated timelines and is committed to maintaining the highest quality manufacturing standards. Importantly, Aurobindo has stated there is no impact on the company's financials or operations due to this inspection. The filing was made under SEBI's Regulation 30 disclosure requirements.
Routine regulatory inspection with 4 observations is generally manageable; however, the nature of the observations (not disclosed) will be key. No immediate financial or operational impact has been flagged, so near-term impact on the stock is likely limited, though investors should watch for the company's response and any follow-up actions from the US FDA.